Ascletis Pharma Inc.

Investors

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
2022-02-04
Voluntary Announcement - Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA
2022-01-26
Voluntary Announcement - Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
2022-01-23
Announcement - Inside Information - Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos
2022-01-18
Next Day Disclosure Returns - Others
2022-01-17
Voluntary Announcement - Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
2022-01-17
Voluntary Announcement - Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
2022-01-13
Voluntary Announcement - Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, an in-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
2022-01-11
Voluntary Announcement - Ascletis Announces U.S. IND Filing for In-house Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
2022-01-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
2022-01-05

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1